Publication

78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (D GC) in patients (pts) with advanced biliary tract cancer (BTC) (vol 33, pg s1462, 2022)

Oh, D.
; 
He, A. R.
; 
Qin, S.
; 
Chen, L.
; 
Okusaka, T.
; 
Vogel, A.
; 
Kim, J. W.
; 
Suksombooncharoen, T.
; 
Lee, M. A.
; 
Kitano, M.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Oh, D.
He, A. R.
Qin, S.
Chen, L.
Okusaka, T.
Vogel, A.
Kim, J. W.
Suksombooncharoen, T.
Lee, M. A.
Kitano, M.
Burris, H. A.
Bouattour, M.
Tanasa, S.
Zaucha, R. E.
Avallone, A.
Cundom, J. E.
Rokutanda, N.
Zotkiewicz, M.
Cohen, G.
Valle, Juan W
Affiliation
Division Of Medical Oncology, Department Of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 110-744 - Seoul/KR
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Oh D, He AR, Qin S, Chen L, Okusaka T, Vogel A, et al. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (D GC) in patients (pts) with advanced biliary tract cancer (BTC) (vol 33, pg s1462, 2022). Annals of Oncology. 2023 Jul;34(7):633-. PubMed PMID: WOS:001033922200001.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626531
Embedded videos